HI
ABCL icon

Harbour Investments’s AbCellera Biologics ABCL Stock Holding History

Harbour Investments’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$443 Buy
+127
New +$457 ﹤0.01% 4279
2021
Q4 		– Sell
-27
Closed -$1K – 2607
2021
Q3 		$1K Buy
27
+2
+8% +$35 ﹤0.01% 3418
2021
Q2 		$1K Buy
25
+20
+400% +$552 ﹤0.01% 3478
2021
Q1 		$0 Buy
+5
New +$199 ﹤0.01% 3579

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Harbour Investments's ABCL Position: Q1 2026 in Review

Harbour Investments opened a new position in AbCellera Biologics (ABCL) in Q1 2026: 127 shares worth $443. The stake represents ﹤0.01% of the portfolio and ranks #4279 among its holdings. This is a return to the name: Harbour Investments previously reported a position in ABCL as recently as Q3 2021.

Harbour Investments first reported a position in ABCL in Q1 2021 and has held it in 4 quarters since. The position peaked at $1K in Q3 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Harbour Investments held 127 shares of AbCellera Biologics worth $443 as of Q1 2026.
  • AbCellera Biologics was a new Harbour Investments position in Q1 2026.
  • AbCellera Biologics made up ﹤0.01% of Harbour Investments's portfolio in Q1 2026, its #4279 holding.
  • Harbour Investments first reported a position in AbCellera Biologics in Q1 2021 and has held it in 4 quarters since.
  • Harbour Investments's AbCellera Biologics position peaked at $1K in Q3 2021.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.